|
🐜
|
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
34 auth.
L. Byers,
L. Diao,
Jing Wang,
P. Saintigny,
L. Girard,
M. Peyton,
Li Shen,
Youhong Fan,
U. Giri,
Praveen K. Tumula,
M. Nilsson,
J. Gudikote,
H. Tran,
R. Cardnell,
D. Bearss,
...
S. Warner,
J. Foulks,
S. Kanner,
V. Gandhi,
N. Krett,
S. Rosen,
Edward S. Kim,
R. Herbst,
G. Blumenschein,
J. Lee,
S. Lippman,
K. Ang,
G. Mills,
W. Hong,
J. Weinstein,
I. Wistuba,
K. Coombes,
J. Minna,
J. Heymach
|
9 |
2012 |
9
🐜
|
|
🐢
|
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
W. Plunkett,
P. Huang,
Y. Z. Xu,
V. Heinemann,
R. Grunewald,
V. Gandhi
|
9 |
1995 |
9
🐢
|
|
🐜
|
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
10 auth.
S. Ponader,
Shih-Shih Chen,
J. Buggy,
K. Balakrishnan,
V. Gandhi,
W. Wierda,
...
M. Keating,
S. O'brien,
N. Chiorazzi,
J. Burger
|
9 |
2012 |
9
🐜
|
|
🐢
|
Gemcitabine: preclinical pharmacology and mechanisms of action.
W. Plunkett,
Pearl S Huang,
C. E. Searcy,
V. Gandhi
|
8 |
1996 |
8
🐢
|
|
🐜
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
32 auth.
N. Jain,
M. Keating,
P. Thompson,
A. Ferrajoli,
J. Burger,
G. Borthakur,
Koichi Takahashi,
Z. Estrov,
N. Fowler,
T. Kadia,
M. Konopleva,
Y. Alvarado,
M. Yilmaz,
Courtney D. DiNardo,
P. Bose,
...
M. Ohanian,
N. Pemmaraju,
E. Jabbour,
K. Sasaki,
R. Kanagal-Shamanna,
K. Patel,
J. Jorgensen,
N. Garg,
Xuemei Wang,
K. Sondermann,
Nichole D Cruz,
Chongjuan Wei,
A. Ayala,
W. Plunkett,
H. Kantarjian,
V. Gandhi,
W. Wierda
|
8 |
2019 |
8
🐜
|
|
🐜
|
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.
16 auth.
A. Kurtova,
K. Balakrishnan,
Rong Chen,
W. Ding,
S. Schnabl,
M. P. Quiroga,
M. Sivina,
W. Wierda,
Z. Estrov,
M. Keating,
...
M. Shehata,
U. Jäger,
V. Gandhi,
N. Kay,
W. Plunkett,
J. Burger
|
8 |
2009 |
8
🐜
|
|
🦁
|
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
V. Gandhi,
E. Estey,
M. Keating,
W. Plunkett
|
8 |
1993 |
8
🦁
|
|
🐜
|
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
16 auth.
H. Kantarjian,
V. Gandhi,
J. Cortes,
S. Verstovsek,
M. Du,
G. Garcia-Manero,
F. Giles,
S. Faderl,
S. O'brien,
S. Jeha,
...
Jan Davis,
Z. Shaked,
A. Craig,
M. Keating,
W. Plunkett,
E. Freireich
|
8 |
2003 |
8
🐜
|
|
🐢
|
Preclinical characteristics of gemcitabine
W. Plunkett,
Peng Huang,
V. Gandhi
|
8 |
1995 |
8
🐢
|
|
🐜
|
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
8 auth.
M. P. Quiroga,
K. Balakrishnan,
A. Kurtova,
M. Sivina,
M. Keating,
W. Wierda,
...
V. Gandhi,
J. Burger
|
8 |
2009 |
8
🐜
|
|
🐬
|
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Rong Chen,
M. Keating,
V. Gandhi,
W. Plunkett
|
8 |
2005 |
8
🐬
|
|
🦁
|
Cellular and Clinical Pharmacology of Fludarabine
V. Gandhi,
W. Plunkett
|
8 |
2002 |
8
🦁
|
